Nautilus Biotechnology 

$3.31
24
-$0.05-1.49% Today

Statistics

Day High
3.43
Day Low
3.12
52W High
4.31
52W Low
0.62
Volume
217,971
Avg. Volume
277,750
Mkt Cap
418.29M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.17
-0.15
-0.13
-0.11
Expected EPS
-0.145
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-118MNet Income

Analyst Ratings

$4.00Average Price Target
The highest estimate is 4.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NAUT. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap18.99B
Illumina provides genomics solutions, including sequencing technologies that compete in the broader biotech market for genetic analysis.
Pacific Biosciences of California
PACB
Mkt Cap702.87M
Pacific Biosciences offers long-read sequencing technologies, directly competing in the genomic analysis space.
Qiagen NV
QGEN
Mkt Cap10.16B
Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, competing in the life sciences sector.
Thermo Fisher Scientific
TMO
Mkt Cap214.25B
Thermo Fisher Scientific offers a wide range of biotechnology products, including analytical instruments and reagents, competing in the research and diagnostics markets.
Bio-Rad Laboratories
BIO
Mkt Cap8.54B
Bio-Rad Laboratories provides a variety of instruments and reagents for the life science research and clinical diagnostics markets, making it a competitor in biotech supplies.
Guardant Health
GH
Mkt Cap11.72B
Guardant Health specializes in liquid biopsies and cancer diagnostics, competing in the precision medicine and genomics field.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is involved in CRISPR/Cas9 technology, competing in the genomic medicine sector, particularly in gene editing.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is focused on developing gene-based medicines, directly competing in the gene editing and therapy market.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine works on gene editing technologies, competing in the development of genomic medicines for various diseases.

About

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Show more...
CEO
Mr. Sujal M. Patel
Employees
134
Country
US
ISIN
US63909J1088

Listings

0 Comments

Share your thoughts

FAQ

What is Nautilus Biotechnology stock price today?
The current price of NAUT is $3.31 USD — it has decreased by -1.49% in the past 24 hours. Watch Nautilus Biotechnology stock price performance more closely on the chart.
What is Nautilus Biotechnology stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nautilus Biotechnology stocks are traded under the ticker NAUT.
Is Nautilus Biotechnology stock price growing?
NAUT stock has fallen by -12.57% compared to the previous week, the month change is a +42.46% rise, over the last year Nautilus Biotechnology has showed a +270.47% increase.
What is Nautilus Biotechnology market cap?
Today Nautilus Biotechnology has the market capitalization of 418.29M
When is the next Nautilus Biotechnology earnings date?
Nautilus Biotechnology is going to release the next earnings report on May 05, 2026.
What were Nautilus Biotechnology earnings last quarter?
NAUT earnings for the last quarter are -0.11 USD per share, whereas the estimation was -0.14 USD resulting in a +21.43% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Nautilus Biotechnology revenue for the last year?
Nautilus Biotechnology revenue for the last year amounts to 0 USD.
What is Nautilus Biotechnology net income for the last year?
NAUT net income for the last year is -118M USD.
How many employees does Nautilus Biotechnology have?
As of April 02, 2026, the company has 134 employees.
In which sector is Nautilus Biotechnology located?
Nautilus Biotechnology operates in the Health Care sector.
When did Nautilus Biotechnology complete a stock split?
Nautilus Biotechnology has not had any recent stock splits.
Where is Nautilus Biotechnology headquartered?
Nautilus Biotechnology is headquartered in Seattle, US.